All articles

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

One Patient Death Due To Kidney Injury In CytomX’s Ongoing Development Of CX-2051

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Scroll to Top